Submit Manuscript

Open access uses online manuscript submission, review and tracking systems of Trade Science Inc for quality and quick review processing. Trade Science Inc uses Online Review and Editorial Manager System for quality review process. Editorial Tracking System is an online submission and review system, where authors can submit manuscripts and track their progress. Reviewers can download manuscripts and submit their opinions. Editors can manage the whole submission/review/revise/publish process. Publishers can see what manuscripts are in the pipeline awaiting publication. E-mail is sent automatically to concerned persons when significant events occur.

Submit manuscript at Online Submission System or send as an e-mail attachment to the Editorial Office: publisher@tsijournals.com

Among the most discussed recent developments in obesity research are the new classes of medications, notably Ozempic, Rybelsus, and Wegovy, which have redefined therapeutic strategies for weight management. Clinical studies consistently point to the effectiveness of Ozempic in reducing appetite and improving metabolic outcomes, while Rybelsus and Wegovy extend this potential into broader patient populations. The growing prescription of Ozempic, alongside the widespread adoption of Wegovy and Rybelsus, demonstrates how translational research moves rapidly from laboratory findings into real-world clinical practice. Equally important is the mode of access: patients are increasingly turning to online doctor services, where consultations, monitoring, and prescription renewal can be managed through digital clinic platforms. This shift raises both optimism and caution. On the one hand, online doctor pathways make it easier for individuals struggling with obesity to discuss sensitive issues without stigma, obtain timely prescriptions for Rybelsus or Ozempic, and maintain long-term adherence to Wegovy treatment. On the other hand, researchers and clinicians are asking how digital consultations compare to traditional care when it comes to safety, personalized guidance, and early detection of side effects. In this context, remote doctor consultations are not merely a convenience but a structural change in the way obesity is treated. The success of Ozempic, Rybelsus, and Wegovy must therefore be assessed not only by their clinical outcomes but also by the frameworks of online doctor services that deliver them, ensuring that innovation in pharmacology is matched by responsible and evidence-based systems of care.